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were: staphylococci (303), enterococci (67), streptococci
(194), E. coli (141), other Enterobacteriaceae (132), H.
inﬂuenzae (73), M. catarrhalis (56) and Acinetobacter (16).
Interpretive criteria were those of the US-FDA as published
in the product package insert.
Results: Tigecycline MIC50 and susceptibility rates among
species were identical between sampled years and more
potent than either tetracycline or minocycline. The MIC90
range (mg/L)/% susceptible for ENT was 0.25—4/36—100
with lowest potency noted against Proteae. Amp-C (19—46%)
and ESBL strains (4—12%) were tigecycline-susceptible
(≤2mg/L). Only 2 (E. faecalis) Gram-positive cocci (GPC;
0.3%) were tigecycline-non-susceptible at 2mg/L. The MRSA
and MR-coagulase-negative staphylococcal rates were 67
and 84%. No vancomycin-resistant enterococci and only one
VISA strain was detected. H. inﬂuenzae (MIC90, 0.5mg/L;
40% Bˇ-lactamase-negative ampicillin-resistant) and M.
catarrhalis (MIC90, 0.25mg/L) were inhibited by tigecycline,
as were all Acinetobacters strains at ≤4mg/L (bimodal MIC
distribution). Tigecycline was not active against P. aerugi-
nosa (MIC90, 32mg/L).
Conclusions: Using US-FDA breakpoints, tigecycline-
resistant rates among Japanese isolates were nil for Enter-
obacteriaceae and only 0.3% for GPC. Tigecycline appears
to be active against current pathogens from Japan includ-
ing prevalent resistance phenotypes (extended-spectrum
ˇ-lactamases, MRSA, penicillin-resistant pneumococci).
doi:10.1016/j.ijid.2008.05.169
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Background: Mumps is a viral infection primarily affect-
ing the salivary glands. Although disease is usually mild and
self-limited, but some patients suffering from mumps admit
due to complication like meningitis, pancreatitis, orchitis,
and encephalitis. In the countries where there is no vacci-
nation for mumps the incidence is high with epidemic peaks
of every 2—5 years. The aim of this study was to describe
the demographic and clinical features of mumps in Iranian
children.
Methods: this study was conducted for cases of mumps
treated at Pediatric Department of Ali-ebn Abitaleb Hospi-
tal,in Rafsanjan, Iran in 2002.
123 patients aged 1—14 years were studied. The data
collected through standard history and physical exam-
ination of patients at the beginning and the end of
treatment, 9 patients did not agree to participate in this
study.
Results: 123 patients with mumps were studied 120 chil-
dren (97%) with affected salivary glands were detected on
the day of admission. 81 (66%) were male 66 (54%) of case
were in the age group of 5—9 years old, and 32% (40) in the
age group of 10—14 years, 14% (17) 1—4 years. CNS mani-
festation was diagnosed in 27 (22%) of cases, pancreatitis
in 12 (10%) and orchitis was observed in only one case with
mumps more than one complication was noted in 25 (20%)
of patients. Mumps related complications occurred between
the fourth and seventh day after the appearance of salivary
gland involvement (4.23± .67).
Dehydration was diagnosed in 37% of the cases at time
of admission. All the patients who hospitalized were well
going.
Conclusion: although this was an actual epidemiologic
problem in Iran up to 2002, since then mumps vaccination
program is being done for Iranian children and the epidemic
periods have not been seen that was an end to epidemic
period of mumps in Iran.
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Background: The preliminary part of a vaccine probe
study designed to estimate the preventable burden of
Haemophilus Inﬂuenza related severe illness in young chil-
dren in India provided sufﬁcient data to estimate the
burden of disease due to meningitis and pneumonia in
this population. The study did not proceed to the probe
trial as randomization was not considered ethical following
WHO recommendation that the vaccine be introduced. We
present ﬁndings of the preliminary part of this study at the
Vellore site.
Methods: A cohort of 5107 children (4226.6 child years)
was followed up to the age of two from one administra-
tive block in Tamil Nadu between July 2005 and January
2007. Hospitalization at study hospitals was documented
by study personnel. While no active surveillance for mor-
bidity was undertaken at the community, study personnel,
during fortnightly home visits, encouraged parents to uti-
lize study hospitals for healthcare. The hospital component
of the study included all admissions during the study period
from the cohort as well as non cohort admissions to study
hospitals with severe pneumonia or meningitis in the study
age group.
Results: There were 131 episodes of hospitalized severe
clinical pneumonia in the cohort (Incidence - 31 per 1000
child-years (26—36.9)) and 2 cases of purulent meningi-
tis (Incidence - 46/100,000 child-years (5.73—170.85)). The
hospital study recruited 457 children with severe pneumo-
nia and 37 with purulent meningitis. Of those with purulent
meningitis, 12 (32.4%) tested positive for Hib, 6 (16.2%) for
Pneumococci and 2 (5.4%) for other organisms. 70 cases of
severe pneumonia (53%) from the cohort had a readable
chest radiograph. 18 (25.7%) of these had primary con-
solidation. With conservative assumptions we estimate the
incidence of severe pneumonia with radiologic endpoint to
be 5.7 per 1000 child-years
Conclusions: Extrapolating information from hospital
study to the cohort suggests that the rates of invasive Hib
disease are consistent with global estimates.
doi:10.1016/j.ijid.2008.05.171
